Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE447.952.3 (+0.52 % )
PREV CLOSE (Rs.) 445.65
OPEN PRICE (Rs.) 451.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 447.80 (25 )
VOLUME 56950
TODAY'S LOW / HIGH (Rs.)442.50 452.50
52 WK LOW / HIGH (Rs.)389.7 838
NSE448.30 2.6 (+0.58 % )
PREV CLOSE(Rs.) 445.70
OPEN PRICE (Rs.) 446.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 448.30 (1758 )
VOLUME 1291486
TODAY'S LOW / HIGH(Rs.) 442.30 452.70
52 WK LOW / HIGH (Rs.)389.35 838

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.56
TTM EPS (Rs.) 28.20
P/E Ratio 15.89
Book Value (Rs.) 206.07
Face Value (Rs.) 1
MCap (Rs. in Mn) 262471.20
Price/Earning (TTM) 12.48
Price/Sales (TTM) 2.10
Price/Book (MRQ) 2.17
PAT Margin (%) 12.48
ROCE (%) 14.85
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : KFIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
29Nov11-29-2019$Aurobindo Pharma’s arm to acquire business assets from Profectus BioSciences Aurobindo Pharma’s arm to

Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., a clinical-stage vaccine development company. The assets are acquired for an upfront cash consideration $11.29 million with potential earn outs on achieving certain milestones.

The acquisition provides access to - Proprietary & Innovative technology platforms for Prophylactic use & Therapeutic use along with Global R&D center.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc...
29Nov11-29-2019$Aurobindo Pharma surges on its arm agreeing to acquire business assets from Profectus BioSciences Aurobindo Pharma surges on i

Aurobindo Pharma is currently trading at Rs. 456.50, up by 6.30 points or 1.40% from its previous closing of Rs. 450.20 on the BSE.

The scrip opened at Rs. 455.05 and has touched a high and low of Rs. 460.00 and Rs. 454.85 respectively. So far 8098 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.

Last one week high and low of the scrip stood at Rs. 460.00 and Rs. 429.10 respectively. The current market cap of the company is Rs. 26378.96 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.95% and 13.18% respectively.

Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., a clinical-stage vaccine development company. The assets are acquired for an upfront cash consideration $11.29 million with potential earn outs on achieving certain milestones.

The acquisition provides access to - Proprietary & Innovative technology platforms for Prophylactic use & Therapeutic use along with Global R&D center.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 456.50, up by 6.30..
29Nov11-29-2019$IL&FS Engineering, Aurobindo Pharma and ONGC to see some action today IL&FS Engineering, Aurobindo

IL&FS Engineering and Construction Company’s subsidiary -- Bangalore Elevated Tollway (BETPL) has been awarded an amount of Rs 492 crore towards Claim filed by the company against National Highways Authority of India (NHAI). The company has 24% stake in BETPL and is entitled to around Rs 118 crore from the total claim awarded by the tribunal.

Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., a clinical-stage vaccine development company. Only assets are acquired for an upfront cash consideration $11.29 million with potential earn outs on achieving certain milestones.

Oil and Natural Gas Corporation (ONGC) has issued $300 million notes at a coupon of 3.375% per annum payable semi-annually in arrears on November 27, 2019 under the $2,000,000,000 Medium Term Note Programme. The Notes are rated ‘Baa1’ from Moody's Investors Service and ‘BBB-’ from S&P Global Ratings.

Muthoot Finance is planning to raise up to Rs 790 crore through non-convertible debentures (NCDs). The funds raised through this issue will be utilized primarily for lending activities. The base size of the issue is Rs 100 crore, with an option to retain oversubscription of up to Rs 690 crore. The issue will help the company to have long-term funds and diversify borrowing basket as well.

Edelweiss Housing Finance (EHFL), a subsidiary of Edelweiss Financial Services has entered into a strategic agreement with Bank of Baroda for co-lending of home loans to self-employed entrepreneurs and salaried customers. EHFL is one of the early movers to enter into a Co-Lending arrangement with a Bank in the housing finance space.

Mangal Credit and Fincorp has signed a Memorandum of Understanding (MoU) to acquire 26 Acre and 2 Gunta land situated at Village Adali, District Sindhudurg in the state of Maharashtra. The said land holds good amount of reserves of Iron ore and hence the company is acquiring this land as a strategic investment.

Bank of Baroda has raised Rs 1,650 crore by issuing Basel-III compliant bonds. The bank issued 16,500 bonds at 8.70% unsecured subordinated fully paid-up additional tier 1 Basel-III non-convertible perpetual taxable bonds' with an issue size of Rs 1,650 crore. To comply with Basel-III capital regulations, bank globally needs to improve and strengthen their capital planning processes.

IL&FS Engineering and Construction Company’s subsidiary -..
28Nov11-28-2019$Aurobindo Pharma submits transcript of analyst call Aurobindo Pharma submits tra

With reference to letter dated November 8, 2019 wherein the company has intimated the schedule of Investors/ Analysts call on November 13, 2019, Aurobindo Pharma has informed about submission of the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2019 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/. 

The above information is a part of company’s filings submitted to BSE.

With reference to letter dated November 8, 2019 wherein the com..
25Nov11-25-2019$Aurobindo Pharma aims to become debt free in next 3 years Aurobindo Pharma aims to bec

Aurobindo Pharma is aiming to become a debt-free company in the next three year’s barring the amount it is spending on acquisition of Sandoz products. In September last year, the company’s US subsidiary entered into an agreement to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, a Novartis Division, for $900 million.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is aiming to become a debt-free company in the..
Financials More
Rs. in Millions
QTR Sep 19 ANNUAL 19
Net Profit3981.315297.3
Gross Profit 5220.6 19646.2
Operating Profit 6648.525085.7
Net Sales 32216.6122578.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 2761.55 (4.11%)
M.Cap ( in Cr)
6903.88
Sanofi India (BSE)
 7018.65 (0.70%)
M.Cap ( in Cr)
16164.39
Divis Lab (BSE)
 1806.35 (1.30%)
M.Cap ( in Cr)
47952.92
Hester Biosciences (BSE)
 1574.70 (1.33%)
M.Cap ( in Cr)
1339.58
Torrent Pharma (BSE)
 1867.95 (0.94%)
M.Cap ( in Cr)
31607.34
Shareholding Pattern More
PROMOTERS 51.87 %
NON-INSTITUTION 13.18 %
MUTUAL FUNDS/UTI 12.66 %
FI/BANKS/INSURANCE 0.33 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes